Starling Oncology, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-9.8M | $-2.5M | $-16.5M | $-17.0M | $-19.6M | — | $-16.1M | $-15.5M |
| Depreciation & Amortization | $1.8M | $1.6M | $1.7M | $1.8M | $1.8M | — | $1.6M | $1.5M |
| Depreciation | $1.1M | $901.0K | $1.0M | $1.0M | $1.0M | — | $800.0K | $745.0K |
| Amortization | $716.0K | $715.0K | $717.0K | $773.0K | $773.0K | — | $774.0K | $773.0K |
| Stock-Based Compensation | — | $1.7M | — | — | $1.5M | — | — | — |
| Net Cash from Operating Activities | $11.9M | $-2.2M | $-12.6M | $-10.2M | $-5.0M | $4.0M | $819.0K | $-15.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $908.0K | $1.0M | $604.0K | $1.2M | $328.0K | — | $-402.0K | $1.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-1.0M | — | — | $-202.0K | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $-28.0K | — | — | $-4.7M | — | — | — |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $11.0M | $-3.3M | $-13.2M | $-11.4M | $-5.3M | — | $1.2M | $-17.5M |